Embecta Q4 beats; discontinues patch pump; restructuring saves $60-65M annually; FY2025 EPS guidance $2.70-2.90

Embecta Corp.

2024-FY EPS reported $1.34 revenue$1,123,100,000

Q4 reported rev $286.1M (+1.5%), GAAP EPS $0.25, adjusted EPS $0.45.
FY2024 rev $1,123.1M (+0.2%), adjusted EPS $2.45, GAAP EPS $1.34.
Discontinues insulin patch pump; expects $35-45M pre-tax charges in FY2025; annualized savings $60-65M.
FY2025 guidance: rev $1,093-1,110M, adjusted EPS $2.70-2.90, adj. EBITDA margin 35.5-36.5%.
Board declares $0.15/share dividend payable Dec 18, 2024 to holders of record Dec 6, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.